Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down
Zacks Investment Research | Nov 01, 2018 09:15PM ET
Geron Corporation (NASDAQ:GERN) reported a loss of 3 cents per share for the third quarter of 2018, narrower than the Zacks Consensus Estimates of a loss of 5 cents and the year-ago quarter loss of 4 cents.
Quarterly revenues increased 1.2% from the year-ago quarter to $0.17 million, which missed the Zacks Consensus Estimate of $0.22 million. Revenues comprised royalty and license fee revenues received under various non-imetelstat license agreements.
Shares were down 1.6% in pre-market trading on Nov 2. So far this year, Geron’s shares have risen 2.8% against the industry ’s decline of 16.2%.
Research and development (R&D) expenses increased 2.7% to $2.7 million. The rise was due to variation in costs for the proportionate share of clinical development of imetelstat under collaboration with Janssen. General and administrative (G&A) expenses fell 10.6% to $4.3 million.
The company ended the quarter with $184.8 million in cash and investments compared with $181.4 million at the end of the second quarter.
Pipeline Update
In September, Geron announced that Johnson & Johnson (NYSE:JNJ) had decided to discontinue the collaboration agreement to co-develop Geron’s sole pipeline candidate, imetelstat. With the termination of the agreement, Geron regained global development rights to imetelstat and decided to continue developing the candidate independently.
Imetelstat is being evaluated in two clinical studies. Phase II IMbark and phase II/III IMerge are evaluating the candidate in myelofibrosis and myelodysplastic syndromes (“MDS”), respectively.
Geron remains confident about the potential of imetelstat in MDS indication based on supportive data from initial and expansion arms of phase II portion of IMerge study. The company expects to initiate the phase III portion of the IMerge study by mid-2019.
Earlier this month, the company announced the acceptance of two oral presentations at the American Society of Hematology ("ASH") meeting to be held in December. This has boosted investors’ confidence in imetestat development which was evident from the 20% rally in share price on Nov 1.
Our Take
With the termination of the agreement, Geron lost a strong and experienced partner as well as its major source of funds. Moreover, the cash resources, as of third-quarter end, will be sufficient to initiate the phase III study in MDS but it is not enough to support the continuation of the study. Meanwhile, operating expenses are likely to increase as J&J shared half of the imetelstat development costs in the past.
Get The News You Want
We expect that the company may face serious difficulties if it is unable to find new avenues for funds like new partnerships or share sale.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.